HOME >> BIOLOGY >> NEWS
In limiting life span, study finds booming bacteria innocent

ndetectable to a million or more per fly.

Using a scanning electron microscope to examine the insects outer surfaces, the researchers showed that some of the bacteria were even banding together, forming continuous biofilms. Yet treatments that reduced the number of bacteria had no effect on life span, they found. That discovery led the researchers to conclude that, at least under optimal laboratory conditions, Drosophila can tolerate a significant number of bacteria and mount a strong innate immune response against them without cutting their 65-day lives any shorter.

There has been some thinking in general that life span is regulated according to trade-offsthat the body has only so much energy to devote to different processes, Tower said. If you devote a lot [of energy] to controlling bacteria, preventing them from growing to a toxic level, then that energy isnt available to maintain tissues and organs. However, we found no effect on the animals longevity even when their bacteria are taken from one extreme to the other.

Nevertheless, he added, the bacterial infestations seen in the aged flies have to be a quality of life issue.


'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
7-Aug-2007


Page: 1 2

Related biology news :

1. UCI researchers define estrogens role in limiting heart disease in women
2. New study warns limited carbon market puts 20 percent of tropical forest at risk
3. Clones on task serve greater good, evolutionary study shows
4. Pollution causes 40 percent of deaths worldwide, study finds
5. A study by the MUHC and McGill University opens a new door to understanding cancer
6. New study suggests Concord grape juice may provide protection against breast cancer
7. Preclinical study links gene to brain aneurysm formation
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
Cached News: